The tweet was deleted by the author.
But we saved everything 🙂.
Bicara Therapeutics announced its financial results for the third quarter of 2026 and provided a business update on its operations.
The company reported substantial enrollment progress in the FORTIFI-HN01 pivotal trial for first-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma. Bicara Therapeutics expects topline results from an interim analysis of this trial in mid-2027.
View post on X Loading...
Earlier this year, Bicara Therapeutics initiated the FORTIFI-FLEX trial targeting HPV-negative head and neck cancer with a specific dosing regimen. The company had previously scheduled its third quarter financial results and business update for November 9, as outlined in a conference call announcement. These developments reflect continued progress in the firm’s clinical and corporate activities.